Incorporate yoga into your daily life: Andhra CM
VIJAYAWADA: Chief Minister N Chandrababu Naidu has called for widespread participation in the 11th International Yoga Day in Visakhapatnam on June 21. With Prime Minister Narendra Modi in attendance as the chief guest, Naidu emphasised the theme 'Yoga for One Earth, One Health', urging people to incorporate yoga into their daily life for enhanced health and longevity.
The Yogandhra initiative, running from May 21 to June 21, aims to engage at least two crore people through extensive yoga sessions across the State.
Naidu's appeal, shared via his X post, highlights the event's significance, building on previous efforts to promote the global and cultural importance of yoga. The Vizag event, targeting five lakh participants, is set to be a historic celebration with Rs 25 crore allocated for preparations, and Rs 10 lakh people trained in yoga.
Naidu's vision is to make Andhra Pradesh a leader in yoga practice, fostering a healthier community, and inspiring nationwide adoption.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
an hour ago
- The Print
Denied ambulance, tribal man travels 90 km on ST bus with newborn daughter's body in carry bag
'I lost my child due to the negligence and apathy of the health system,' muttered Sakharam who couldn't get an ambulance to shift his wife, who went into labor, to Khodala PHC on June 11. Denied ambulance by Nashik Civil Hospital, the tribal man travelled on a state transport bus, carrying the body of his stillborn daughter home in a carry bag. Mumbai, Jun 16 (PTI) Sakharam Kavar's voice trembled with deep anguish and helplessness as he recalled the 90-km agonising journey no parent should endure. The 28-year-old daily wage labourer from the Katkari tribal community lives in a hut in Jogalwadi hamlet in Palghar district, around 200 km from Mumbai. Until recently, he and his wife Avita, 26, worked at a brick kiln in Badlapur in Thane district with their two children. With their third child due soon, they returned to their village three weeks ago in hopes of a safe delivery. But on June 11, when Avita went into labor, their ordeal began. 'We called for an ambulance since morning, but no one came,' Sakharam said. The village ASHA worker was initially unavailable. When she tried calling the emergency number 108, she reportedly received no response initially but later arranged a private vehicle to take Avita to Khodala Public Health Centre. 'There was movement in my womb on the way,' Avita said, adding that she was kept waiting for more than an hour after reaching the PHC. She was later referred to Mokhada Rural Hospital. 'They isolated me in a room. When my husband protested, they called the police, who beat him,' she alleged. Doctors at Mokhada advised a transfer to Nashik Civil Hospital after they couldn't record the heartbeats of the foetus. Since the ambulance was unavailable, an ambulance was summoned from Aase village, 25 km away. Avita reached Nashik late in the evening where she delivered a stillborn baby girl around 1:30 a.m. on June 12. In the morning, the hospital handed over the baby's body to Sakharam, but refused an ambulance to take the body home. 'I went to the ST stand, bought a Rs 20 carry bag, wrapped my baby in cloth, and travelled nearly 90 kilometres in an MSRTC bus,' he said. 'Nobody asked what I was carrying.' The baby was buried in their village the same day. On June 13, Sakharam returned to Nashik to bring his wife home. 'They again refused an ambulance,' he claimed. Weak and recovering, Avita made the journey back by bus. 'They didn't even give her any medicine,' Sakharam added. Dr. Bhausaheb Chattar of Mokhada Rural Hospital confirmed the sequence of events. 'The baby was dead in the womb. The ambulance at our centre had broken down, so we arranged one from Aase. He indeed travelled with the baby's body on a bus,' he told PTI. Chattar also claimed the hospital had offered an ambulance for the return trip, but Sakharam allegedly refused and signed a waiver—something the father denies. He said all possible assistance was provided to the tribal couple. 'I lost my child because of their neglect,' Sakharam said quietly. PTI DC NSK This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Business Standard
an hour ago
- Business Standard
Zydus Life subsidiary ZHL appoints Swati Dalal as MD
Zydus Lifesciences announced that its subsidiary, Zydus Healthcare, has appointed Swati Dalal as additional director and MD for a five-year term, effective 16 June 2025. The appointment was approved by the nomination and remuneration committee (NRC). Swati Dalal is part of the senior management team at Zydus Lifesciences and brings extensive leadership experience to her new role as Managing Director of Zydus Healthcare. Swati Dalal is a seasoned commercial leader with over 30 years of rich and diverse experience in the healthcare and pharmaceutical industry. She began her career with Wockhardt Nutrition before moving to the erstwhile Boots, where she continued through successive mergers with Knoll, Solvay, and Abbott, progressively taking on leadership roles across the organisation. During her tenure at Abbott, she held various senior positions across both commercial and support functions. These included commercial director sales & marketing, as well as leadership of new product introductions (NPI), business development, and commercial excellence. She later served as managing director of Abbott Nutrition and Abbott Primary Care, and most recently, as managing director of Abbott India. Swati has also been a strong proponent of employee development and inclusion. She has led and contributed to initiatives such as women leaders of Abbott, the early career network, and has actively championed Abbotts diversity, equity, and inclusion (DEI) agenda in India. Swati holds a pharmacy degree from P.K.M. Kundnani College of Pharmacy, Mumbai and a post-graduate degree in Management Studies from Jamnalal Bajaj Institute of Management Studies in Mumbai. Swati Dalal is not related to any of the directors of Zydus Lifesciences or its wholly owned subsidiary, Zydus Healthcare. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.51% to Rs 970 on the BSE.
Business Standard
an hour ago
- Business Standard
Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China
Lupin announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI) capsules in China for the treatment of chronic obstructive pulmonary disease. As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions. Fabrice Egros, president of corporate development, Lupin, said, "We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions. Wang Li, president of SUP, said, "We are truly honored to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.05% to Rs 2,001.45 on the BSE.
